Polivy logo

Patient Population

The POLARIX trial demonstrates that POLIVY-R-CHP benefits a broad, representative population of 1L DLBCL patients1,2,3

Watch experts perspectives

Specialist views covering a range of POLARIX trial topics

A Smiling grey-haired man wearing a blue button-up shirt.

Dr Hervé Tilly

University of Rouen, France

A smiling male medical professional wearing a white lab coat and a blue necktie.

Prof. Christopher Flowers

MD, Anderson Cancer Center, University of Texas

A portrait of a smiling middle-aged man in a suit and tie.

Dr Franck Morschhauser

MD, PhD Professor of Hematology,
University of Lille

A smiling blonde woman with short hair wearing a black top and a pink cardigan.

Dr Laurie H. Sehn

MD, MPH Clinical Assistant
Professor with the BC Cancer Agency and University
of British Columbia

POLIVY-R-CHP benefits a broad 1L DLBCL patient population covering diverse age groups, geographic backgrounds, and clinical profiles1,3

SAFETY

Broad patient population

Broad patient population

 

POLIVY-R-CHP benefits a broad 1L DLBCL patient population covering diverse age groups, geographic backgrounds, and clinical profiles1,3

SAFETY

SAFETY
A man carrying a woman in his arms next to a woman in a pink dress.
A man carrying a woman in his arms next to a woman in a pink dress.

Real patient journeys demonstrating POLIVY’s
impact across diverse 1L DLBCL cases

Explore real-world cases to see how POLIVY transformed patients’ clinical outcomes

Similar efficacy was seen across patient subgroups4,5

Elderly patients ( ≥70 years)4

  • In patients aged >70–80 years, efficacy endpoints favoured POLIVY-R-CHP vs. R-CHOP, including progression-free survival as observed in the ITT population4
  • The analysis of this elderly population confirms the risk-benefit profile of POLIVY-R-CHP that was observed in the ITT population4

High-risk patients (young patients age ≤60 years, high-risk aaIPI 2,3)5,*

  • In a retrospective analysis, no significant differences in efficacy were seen in high-risk patients receiving POLIVY-R-CHP or R-CHOEP at 2 years5
  • Similar efficacy was seen across patient subgroups regardless of aaIPI 2 or 3 status at 2 years5

 

Elderly patients ( ≥70 years)4

  • In patients aged >70–80 years, efficacy endpoints favoured POLIVY-R-CHP vs. R-CHOP, including progression-free survival as observed in the ITT population4
  • The analysis of this elderly population confirms the risk-benefit profile of POLIVY-R-CHP that was observed in the ITT population4

High-risk patients (young patients age ≤60 years, high-risk aaIPI 2,3)5,*

  • In a retrospective analysis, no significant differences in efficacy were seen in high-risk patients receiving POLIVY-R-CHP or R-CHOEP at 2 years5
  • Similar efficacy was seen across patient subgroups regardless of aaIPI 2 or 3 status at 2 years5

 

*A retrospective analysis based on results from the POLIVY-R-CHP arm of POLARIX and the R-CHOEP arm of the Phase III Mega-CHOEP study5

A young man with a basketball, a man with a bicycle, and a woman practicing yoga.

“Our tumor board tries to get the best therapy for our patients. In certain situations, like those with stage III or IV DLBCL, we treat with POLIVY-R-CHP, and we have had great success with the therapy.”

– Dr Joachim Rettl

Hematologist and General Oncologist, Klinikum Klagenfurt am Wörthersee

A young man with a basketball, a man with a bicycle, and a woman practicing yoga.

Safety

How does the safety data for POLIVY-R-CHP compare to that of R-CHOP?

read more

1L=first line; aaIPI=age-adjusted International Prognostic Index; DLBCL=diffuse large B-cell lymphoma; POLIVY-R-CHP=polatuzumab vedotin + cyclophosphamide, doxorubicin, prednisone;
R-CHOEP, rituximab + cyclophosphamide, etoposide, doxorubicin, vincristine, prednisone; R-CHOP=rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone.

 

References:

  1. Tilly H, et al. N Engl J Med. 2022;386:351-63.
  2. Sehn LH, Salles G. N Engl J Med. 2021;384:842-58.
  3. Salles G, et al. Oral presentation at: 66th ASH; December 2024; San Diego, USA.
  4. Hu B, et al. Poster presented at: 17th ICML; June 2023; Lugano, Switzerland.
  5. Lenz G, et al. Leukemia. 2024;38:2709-11.